Key Takeaways
- Turnaround year with sharp profit jump: Revenue grew 20% while EBITDA doubled and PAT rose ~150%, driven by softening Chinese import prices and operating leverage as fixed costs stayed flat.
- Medical Devices is the growth engine: The segment grew 35%, outpacing API's 14%, and its "printer cartridge" model means every new meter installed builds a recurring, higher-margin Strips revenue stream.
- Capacity is the bottleneck, not demand: The company is already facing product shortages and is racing to add SMT lines, backward-integrate, and plan for a future scale of Rs. 5,000 crores, not the current Rs. 500 crores peak.
- Formulation is a drag with a breakeven promise: The segment posted a negative EBITDA of Rs. 19.5 crores for the year, but management expects it to break even in FY25 now that high-speed capacity is in place.
- What to watch next quarter: Whether the formulation business actually hits breakeven, the pace of capacity addition to relieve shortages, and any concrete progress on the medical devices subsidiary spin-off.
Medical Devices: The "Printer Cartridge" Engine
- Installed base drives recurring revenue: The business model mirrors a printer cartridge system: sell the meter first, then continuously sell Strips. With 1.16 crore meters installed, each new meter adds to a growing, recurring income stream.
- Strips are the profit center: Strip margins are substantially higher than meter margins. While meter sales grow ~20%, the Strip business grows ~30%, and that 10% delta is pure profit compounding as the installed base expands.
- BP Monitors provide a simpler, complementary stream: The business grew 36% this year (28% CAGR over 7-8 years) and shares the same customer base as Glucose Monitors since diabetes and hypertension often co-occur. Unlike Glucometers, BP Monitors have no consumable tail, making them less lucrative but still a strong cross-sell.
- Manufacturing integration is deepening: All BP and Glucose meters are now produced in-house from the PCB level using SMT lines, injection molding, and screen printing. Strips are still imported from Korea and cut into sheets in India, but the company is working to bring full Strip manufacturing in-house.
- Margin trajectory is math-driven: As the installed meter base grows, the delta from higher Strip sales keeps expanding. Management's internal math shows the Devices EBITDA margin rising from 12% to 18%-19% over time, driven entirely by own manufacturing and reduced dependence on imports.
Suri: "If I grow 20 lakh meter, 25 lakh, 30 lakhs, but the number of Strips will keep on increasing because for every meter we have installed, so that delta is increasing every time so the margins are increasing."
API: Volume Growth Under Price Pressure
- Volume far outpaced revenue: To achieve 14% API revenue growth, the company had to produce 39% more quantity because of price reductions in the market. Capacities were exhausted, and all expansions are being funded from internal accruals.
- Six molecules dominate the portfolio: Approximately 90% of API revenue comes from six leadership molecules. The remaining 10% includes key products like Loratadine, Montelukast, and Atorvastatin, plus newer entries such as Dapagliflozin and Apixaban.
- Fexofenadine is the new blockbuster: The product received US FDA approval in 2022, exports started last year, and it posted 300% growth this year. It exemplifies the strategy of building new products to diversify beyond the six core molecules.
- Regulatory track record is clean: The company achieved a "hattrick of nil observations" (zero Form 483s) across its last three FDA inspections at two plants, a strong signal for future ANDA-driven export growth.
- New products will scale slowly: Management aims to grow the revenue share of new products from 10% to 30% over the next five years as they mature, but declined to give forward-looking figures, noting that "markets are real."
Suri: "Even to get 14% growth in the annual revenue, we had to produce 39% more quantity to keep our target. So, we were on the toes for whole of the year."
Formulation & OTC: The Turnaround Bet
- The segment is a material drag: Formulation posted a negative EBITDA of Rs. 19.5 crores for the full year (Rs. 4 crores loss in Q4). The losses stem from salary costs that became too high after a capacity addition this year, plus a sub-scale distribution business that has not reached breakeven.
- The fix is higher throughput, not more expansion: Management is not doing major new expansions. Earlier low-capacity machines could not recover costs and salaries. New high-speed machines with higher capacities are now installed, enabling the volume needed to cover fixed costs.
- Jan Aushadhi is a profitable bright spot: The government-scheme business more than tripled this year and is described as very profitable, providing a base load for the new capacity.
- Breakeven is promised for FY25: Management stated that formulation breakeven is "on the card" for this financial year, and the distribution business losses should come down if not reach breakeven. Topline could achieve 2.5x to 3x in the coming two years since the CAPEX is already done.
- Long-term optionality includes divestment: The formulation and OTC businesses are housed in separate subsidiaries. Management is open to eventually divesting, getting a partner, or keeping them separate, but the immediate priority is making them profitable.
Suri: "Formulation and OTC, we are, I would say not on the head runway and we are just trying to see okay, how can we make this business profitable and maybe at some stage divest it or get a partner or get into a separate Company."
Capacity, Reach & the Export Opportunity
- Current capacity is already strained: The company entered Q1 FY25 facing product shortages and capacity constraints because demand has picked up. More SMT lines and dedicated meter production lines are being added.
- Retail expansion is a five-year project: The target is to grow the retail footprint from 1,25,000 to 300,000 outlets, with a specific focus on doubling up sales efforts in South India, a larger and more educated market.
- Exports could transform the scale of the business: A single order from a chain like Walmart, CVS, or Walgreens could be as large as the entire India market. The company would happily double or triple capacity for such an order, but needs full in-house Strip manufacturing and CE certification for Europe first.
- The ambition is to plan for 10x the current peak: Management is shifting its planning horizon from a Rs. 500 crores peak to Rs. 5,000 crores, building capacities accordingly. The Middle East and South America are described as "absolutely uncovered" markets.
Suri: "Now, we are coming out of the cocoon, you don't have the peak of Rs. 500 crores, we have to plan for Rs. 5,000 crores. So, for Rs. 5,000 crores we had to earn capacities."
Financial Health & Segment Math
- The company is now debt-free: All old bank debts have been cleared, leaving the company with only negligible debt (car loans) and Rs. 35-44 crores in fixed deposits. Annual EBITDA is almost the same as cash generation.
- Operating leverage is the margin story: With a 20% revenue increase, EBITDA doubled because expenses were already covered and are not increasing with volume. Gross margin improvement from softer Chinese import prices added further lift, taking the overall EBITDA margin from 5% to 12.31%.
- Segment margins are standalone figures: The reported API margin (18%) and Devices margin (12%) do not include unallocated corporate expenses or OTC business losses, which bring down the overall company EBITDA. Management did not provide a full reconciliation of these corporate costs.
- Devices is capital-efficient: The business has an asset turnover greater than 10x and typically operates with cash-negative working capital because it imports from China and Korea but sells on advance with no credit extended to the market.
Strategic Initiatives & New Bets
- A medical devices subsidiary spin-off is in process: Shareholder approval has been taken, and regulatory procedures are underway. The structure will be a knock-stock arrangement rather than a demerger. The business is expected to start moving into the new entity within this financial year, after which it can pursue its own fundraising.
- Continuous Glucose Monitoring (CGM) is a long-term R&D project: The R&D team is working on a patch that reads from a phone, but management describes it as "a little away" from current thinking. The cost target is Rs. 1,000 per patch or per month, which may take 2-3 years.
- Strip manufacturing is a platform technology: Learning to make a Strip for Glucometers (circuit, biochemistry, enzymes) enables making Strips for cholesterol testing. The same technology used for an accurate pregnancy test last year can be replicated for dengue or malaria tests.
- A new R&D lab opened in Bangalore in Q4: This joins the existing Okhla lab (focused on biosensors and biochemistry) and the Baddi plant R&D (in-house medical devices production), signaling increased investment in new product development.
- Roche's reported retail withdrawal is seen as an opportunity: If a multinational competitor exits the retail market, Morepen sees a chance to capture share by selling its own meters into the vacated space, though it cannot make Strips compatible with Roche's locked machines.
Suri: "We see that this unique opportunity which we are eyeing upon... a much bigger opportunity than tracking our neck on formulation business or on any other generic business."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Formulation breakeven | Segment to stop losing money now that high-speed capacity is installed | FY25 |
| Formulation revenue scale-up | Topline to reach 2.5x to 3x current levels (~Rs. 100 crores to ~Rs. 300 crores) | Coming two years |
| API peak revenue capacity | Existing gross block can support ~Rs. 1,150 crores in API revenue | With small additions to gross block |
| Medical devices subsidiary move | Business to begin moving into the separate legal entity | Within this financial year |
| Retail footprint expansion | Grow from 1,25,000 to 300,000 retailers | Next 5 years |
| New API product revenue share | Increase from 10% to 30% of API revenue | Next 5 years |
| Meter sales volume ramp | Planned trajectory: 30 lakh meters this year, then 36 lakhs, 40 lakhs, and expanding | Annual progression |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Revenue | ₹1,704 cr, +20% YoY (annual); Q4 revenue +16.5% YoY |
| EBITDA | ₹52 cr, +182% YoY from ₹18 cr; margin 12.31% vs 5% YoY |
| Profit before tax | ₹42 cr, +279% YoY from ₹11 cr; margin 9.88% vs 3% YoY |
| Profit after tax | ₹97 cr (annual), +150% YoY; Q4 PAT margin 6.73% vs 2.25% YoY |
| Earnings per share | ₹1.88 per ₹2 share, +144% YoY (annual) |
| Return on equity | 11%, vs 5% last year (annual) |
| Return on capital employed | 15%, vs 7.31% last year (annual) |
| Medical Devices revenue | ₹443 cr (annual), +35% YoY; Q4 +28% YoY and +28% QoQ |
| API revenue | ₹271 cr, +25% YoY from ₹217 cr; annual ₹940 cr, +14% YoY |
| API volume sold | 432 metric tons (annual), +39% YoY from 311 metric tons |
| Glucometer business revenue | ₹342 cr (annual), out of ₹447 cr Medical Devices total |
| Glucose Strips sold | 36 cr Strips (annual); average 35 cr, expecting up to 40 cr |
| Glucose meters installed base | 1.16 cr cumulative meters in market |
| BP Monitor meters sold | 10.51 lakh meters (annual), +29% YoY from 8 lakh meters |
| Formulation & OTC revenue growth | +10% YoY (annual); Q4 +2% YoY |
| Formulation EBITDA loss | ₹4 cr loss in Q4; ₹19.5 cr loss annual |
| API EBITDA margin | 18%, improved from ~16% last year |
| Medical Devices EBITDA margin | 12%, improved from 8% last year |
| Debt equity ratio | 0.03, negligible debt |
| Asset turnover ratio | ~9x |